PepGen: Stock Slides On FDA Study Hold - I'm Firmly On The Sidelines
Source: SeekingAlpha
2026-03-05 14:49:43 ET
Investment Overview
The stock of PepGen Inc. ( PEPG ) is down >20% in early trading today, after the company released its Q4 and full-year 2025 earnings, and shared the news that the FDA had placed a partial clinical hold on its FREEDOM2-DM1 Phase 2 multiple ascending dose ("MAD"), randomized, placebo-controlled clinical trial of candidate PGN-EDODM1 in patients with myotonic dystrophy type 1 ("DM1")....
Read the full article on Seeking Alpha
For further details see:
PepGen: Stock Slides On FDA Study Hold - I'm Firmly On The Sidelines
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
1.56% G/L:
$17.885 Last:
1,151,803 Volume:
$17.63 Open:
SRPT Latest News
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
